Supplemental Figure S1 from Tusamitamab ravtansine in patients with advanced solid tumors: Phase 1 study of safety, pharmacokinetics, and antitumor activity using alternative dosing regimens
Year: 2023
Type: supplementary-materials
Abstract: Tusamitamab ravtansine maximum plasma concentrations by dose level
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385554300